Want to see MDXH full AI Analyst Report?
MDXH Stock Chart & Stats
$2.31
-$0.10(-4.55%)
At close: 4:00 PM EST
$2.31
-$0.10(-4.55%)
Day’s Range― - ―
52-Week Range$0.40 - $5.33
Previous CloseN/A
Volume27.23K
Average Volume (3M)691.20K
Market Cap
$21.72M
Enterprise Value$180.87
Total Cash (Recent Filing)$29.03M
Total Debt (Recent Filing)$95.11M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Aug 13, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding51,364,520
10 Day Avg. Volume417,410
30 Day Avg. Volume691,198
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)-14.77
Price to Sales (P/S)1.66
P/FCF Ratio-15.43
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.38Price Target Upside46.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.64
Revenue Forecast (FY)$116.15M
Bulls Say, Bears Say
Bulls Say
Proven Multi‑year Revenue Scaling And Strong 2026 GuidanceSignificant multi‑year top‑line expansion demonstrates durable commercial traction and scalable demand for prostate diagnostics. Management’s 2026 core guidance implying 20–26% growth signals ongoing adoption and a sizeable addressable market, supporting sustainable revenue runway over the next several quarters.
High And Improving Gross Margins (~60%)Sustained gross margins near 60% indicate robust unit economics for molecular/epigenetic tests, which underpins long‑term profitability potential as scale improves. Healthy gross margins provide buffer against reimbursement pressure and enable investment in sales, R&D and AI initiatives without immediate margin collapse.
Commercial Integration Success And AI/clinical DifferentiationSuccessful integration of ExoDx customers and cross‑trained salesforces creates operating efficiencies and expands the prostate test menu, increasing cross‑sell potential. Concurrent AI platform work and clinical partnerships (PROTECT trial) can create durable differentiation and higher clinical utility over time.
Bears Say
Strained Balance Sheet: Rising Debt And Negative EquitySubstantially higher leverage and negative equity materially reduce financial flexibility and increase refinancing or dilution risk. Continued dependence on external capital is likely until operating cash flow turns meaningfully positive, elevating long‑term funding and strategic execution risk.
Margin Pressure And Widening Post‑acquisition Operating LossesGross‑margin compression and a larger pro‑forma operating loss after the ExoDx acquisition suggest integration and product‑mix challenges. If tissue tests remain a higher mix, sustaining previous margin levels will be difficult, slowing progress to profitability and increasing ongoing cash burn risk.
Reimbursement/regulatory Risk And Strategic Exit DisruptionA contested Medicare recoupment and the Resolve business exit indicate structural reimbursement uncertainty in parts of the portfolio. Exiting businesses and lab closures reduce diversification and may impose restructuring costs, creating persistent execution and payer‑risk that could impair cash generation.
MDxHealth News
MDXH FAQ
What was Mdxhealth S.A.’s price range in the past 12 months?
Mdxhealth S.A. lowest stock price was $0.40 and its highest was $5.33 in the past 12 months.
What is Mdxhealth S.A.’s market cap?
Mdxhealth S.A.’s market cap is $21.72M.
When is Mdxhealth S.A.’s upcoming earnings report date?
Mdxhealth S.A.’s upcoming earnings report date is Aug 13, 2026 which is in 24 days.
How were Mdxhealth S.A.’s earnings last quarter?
Mdxhealth S.A. released its earnings results on May 13, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.145 by -$0.045.
Is Mdxhealth S.A. overvalued?
According to Wall Street analysts Mdxhealth S.A.’s price is currently Undervalued.
Does Mdxhealth S.A. pay dividends?
Mdxhealth S.A. does not currently pay dividends.
What is Mdxhealth S.A.’s EPS estimate?
Mdxhealth S.A.’s EPS estimate is -0.19.
How many shares outstanding does Mdxhealth S.A. have?
Mdxhealth S.A. has 51,364,520 shares outstanding.
What happened to Mdxhealth S.A.’s price movement after its last earnings report?
Mdxhealth S.A. reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.145. Following the earnings report the stock price went down -49.538%.
Which hedge fund is a major shareholder of Mdxhealth S.A.?
Currently, no hedge funds are holding shares in MDXH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mdxhealth S.A.
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
MDXH Stock 12 Month Forecast
Average Price Target
$3.38
▲(46.10% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.45% Mutual Funds
20.13% Other Institutional Investors
78.23% Public Companies and
Individual Investors